Navigation Links
China Biologic Products Establishes Governance and Nominating Committee and Compensation Committee

TAIAN CITY, Shandong, China, Aug. 13 /Xinhua-PRNewswire-FirstCall/ -- China Biologic Products, Inc. (OTC Bulletin Board: CBPO) (''CBP,'' or the ''Company''), one of the leading plasma-based pharmaceutical companies in the People's Republic of China (''PRC''), today announced that, effective August 7, 2008, its Board of Directors has established a Governance and Nominating Committee and a Compensation Committee, and has appointed each of the Company's current independent directors, Dr. Tong Jun Lin, Dr. Jie Gan and Mr. Sean Shao, as members of each committee. Dr. Lin was appointed to serve as Chair of the Governance and Nominating Committee and Dr. Gan was appointed to serve as Chair of the Compensation Committee.

''We are delighted to have all our board committees in place, with each of our independent directors as chairpersons of their respective committees,'' said Mr. Chao Ming Zhao, the Company's CEO. ''The establishment of these new board committees is another step in furtherance of our new corporate governance policy, as we continue to expand our business and pursue our commercial objectives.''

Mr. Sean Shao, independent director and Chairman of CBP's Audit Committee, has been appointed as a member of the Governance and Nominating Committee and the Compensation Committee. Mr. Shao brings to CBP over thirteen years of experience in financial and operational management in publicly held and private-owned companies. For the past four years Mr. Shao has served as chief financial officer of Trina Solar Limited, ChinaEdu Corporation, a Chinese educational service provider, and Watchdata Technologies Ltd., a Chinese security software company. Prior to this, Mr. Shao served six years as a senior manager at Deloitte Touche Tohmatsu Beijing and three years with Deloitte & Touche Toronto. Mr. Shao received his master's degree in health care administration from the University of California at Los Angeles in 1988 and his bachelor's degree in art from East China Normal University in 1982. Mr. Shao holds a CPA license of American Institute of Certified Public Accountants.

Dr. Jie Gan, independent director and member of CBP's Audit Committee, has been appointed to serve as the Chair of CBP's Compensation Committee and as a member of the Governance and Nominating Committee. Dr. Gan brings a wealth of financial consulting experience to CBP. She serves as an associate professor with tenure in the Department of Finance at the Hong Kong University of Science and Technology. Her areas of research expertise include pharmaceutical company valuation in the areas of accounting statements, cash flow forecasts, and cost of capital estimations. Dr. Gan received her PhD in Financial Economics from the Massachusetts Institute of Technology and her Bachelor's degree from Nanjing University in China.

Dr. Tong Jun Lin, independent director and member of CBP's Audit Committee, has been appointed to serve as the Chair of CBP's Governance and Nominating Committee and as a member of the Compensation Committee. Dr. Lin has over 20 years of medical research experience. He is an associate professor with tenure in the Departments of Microbiology and Immunology and Pediatrics at the Dalhousie University. Dr. Lin has been involved in the studies of immunological mechanisms in the host defense against microbial pathogens and allergens. Dr. Lin received his MD (1984) from The First Military Medical University in Guangzhou, China and PhD (1990) degree from the Institute of Materia Medica Chinese Academy of Medical Sciences in Beijing, China. He received his post-doctoral training at the University of Alberta, Duke University and Dalhousie University.

About China Biologic Products, Inc.

Through its indirect majority-owned subsidiary Shandong Taibang Biological Products Co. Ltd., China Biologic Products, Inc. (the ''Company''), is principally engaged in the research, development, production and manufacturing and sale of plasma-based biopharmaceutical products to hospitals and other health care facilities in China. The Company's human albumin products are mainly used to increase blood volume and its immunoglobulin products are used for the treatment and prevention of diseases.

Safe Harbor Statement

This release may contain certain ''forward-looking statements" relating to the business of China Biologic Products, Inc. and its subsidiary companies. All statements, other than statements of historical fact included herein are ''forward-looking statements," including statements regarding: the significance of the Company's establishment of the new board committees; the ability of the Company to achieve its commercial objectives; the business strategy, plans and objectives of the Company and its subsidiaries; and any other statements of non-historical information. These forward-looking statements are often identified by the use of forward-looking terminology such as ''believes,'' ''expects'' or similar expressions, involve known and unknown risks and uncertainties. Although the Company believes that the expectations reflected in these forward-looking statements are reasonable, they do involve assumptions, risks and uncertainties, and these expectations may prove to be incorrect. Investors should not place undue reliance on these forward-looking statements, which speak only as of the date of this press release. The Company's actual results could differ materially from those anticipated in these forward-looking statements as a result of a variety of factors, including those discussed in the Company's periodic reports that are filed with the Securities and Exchange Commission and available on its website ( ). All forward-looking statements attributable to the Company or persons acting on its behalf are expressly qualified in their entirety by these factors. Other than as required under the securities laws, the Company does not assume a duty to update these forward-looking statements.

For more information, please contact:

Company Contact:

Mr. Y. Tristan Kuo, CFO

China Biologic Products, Inc.

Tel: +86-538-6202-206


Web site:

Investor Relations Contact:

Mr. Crocker Coulson, President

CCG Investor Relations

Tel: +1-646-213-1915 (NY office)



SOURCE China Biologic Products, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. China Kangtai Cactus Biotech Files 2nd Quarter 2007 10QSB and Announces Unaudited Quarterly Results
2. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
3. China Medical Technologies to Participate in the Morgan Stanleys 2007 China Medical Corporate Day
4. China-Biotics, Inc. Signs Intention Agreement to Supply Probiotics to Bright Dairy & Food Co., Ltd.
5. China Technology Announces New Chief Financial Officer
6. China Medical Technologies Reports First Quarter Financial Results
7. China Medical Technologies to Participate in Credit Suisses 2007 Asian Technology Conference
8. China Technology Announces Entry to the Solar Energy Sector
9. China Sky One Medical Receives $1.5 Million Government Grant to Further Develop Six New Cancer Products
10. Kiwa Bio-Tech Named Recommended Brand by the China Green Food Association
11. China Kangtai Cactus Biotech, Inc. Announces Plans for New Product Launch
Post Your Comments:
(Date:11/30/2015)... , Nov. 30, 2015 /PRNewswire/ - Zenith Epigenetics Corp. ... Dr. Norman C.W. Wong to its Board of ... comes to Zenith with a wealth of experience as co-founder ... molecular biology. --> --> ... Zenith Epigenetics, board of directors. Zenith,s long standing expertise in ...
(Date:11/30/2015)... SAN DIEGO , Nov. 30, 2015 ... today that the company has acquired Cypher Genomics, Inc., ... and robust human genomic interpretation software solutions. The ... who will join HLI including Cypher CEO and Co-founder, ... head of HLI,s Pediatric Business.  Financial details of the ...
(Date:11/30/2015)... 2015  AbbVie, is introducing Good Morning Hypothyroidism ... daily routine for managing the life-long condition of hypothyroidism. ... the way the body absorbs it so resources encouraging ... routine are important. The goal of the new website ... their hypothyroidism by establishing a daily routine, spirit of ...
(Date:11/30/2015)... Israel , Nov. 30, 2015 ... leading developer of adult stem cell technologies for neurodegenerative diseases, ... has been awarded an additional grant of approximately $735,000 from ... (OCS). This grant, the second this year, brings the total ... $1.8 million (approximately NIS7 million).  ...
Breaking Biology Technology:
(Date:11/10/2015)... 2015 About signature verification ... to identify and verify the identity of an ... the secure and accurate method of authentication and ... individual because each individual,s signature is highly unique. ... dynamic signature of an individual is compared and ...
(Date:11/4/2015)... York , November 4, 2015 ... a new market report published by Transparency Market Research "Home ... Growth, Trends and Forecast 2015 - 2022", the global home ... US$ 30.3 bn by 2022. The market is estimated ... forecast period from 2015 to 2022. Rising security needs ...
(Date:10/29/2015)... , Oct. 29, 2015  The J. Craig Venter ... titled, "DNA Synthesis and Biosecurity: Lessons Learned and Options ... of Health and Human Services guidance for synthetic biology ... --> --> ... has the potential to pose unique biosecurity threats. It ...
Breaking Biology News(10 mins):